大韩民国首个全国性麻腮风疫苗接种计划:加强公共卫生应对措施的意义。

IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim
{"title":"大韩民国首个全国性麻腮风疫苗接种计划:加强公共卫生应对措施的意义。","authors":"Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim","doi":"10.3346/jkms.2024.39.e235","DOIUrl":null,"url":null,"abstract":"<p><p>On May 1, 2024, the Republic of Korea lifted the infectious disease crisis alert for mpox, almost two years after the first case was reported. The Korea Disease Control and Prevention Agency (KDCA) has led the response, which included diagnosis, epidemiological investigations, treatment, and vaccination. This article particularly reviews the vaccination strategy implemented and proposes suggestions for enhancing future response efforts. Initially, the KDCA recommended pre-exposure prophylaxis for high-risk groups, later expanding to include broader demographics as domestic cases rose. By April 2024, a total of 6,863 individuals had received their first vaccine dose, with 3,875 completing the second dose of third-generation vaccines. Strategies to improve future responses include addressing stigma, securing nationally representative safety data, and conducting vaccine cost-benefit analyses. These measures will help ensure a robust and effective response to future outbreaks.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"39 32","pages":"e235"},"PeriodicalIF":3.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333806/pdf/","citationCount":"0","resultStr":"{\"title\":\"First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response.\",\"authors\":\"Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, Sookyoung Lim\",\"doi\":\"10.3346/jkms.2024.39.e235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>On May 1, 2024, the Republic of Korea lifted the infectious disease crisis alert for mpox, almost two years after the first case was reported. The Korea Disease Control and Prevention Agency (KDCA) has led the response, which included diagnosis, epidemiological investigations, treatment, and vaccination. This article particularly reviews the vaccination strategy implemented and proposes suggestions for enhancing future response efforts. Initially, the KDCA recommended pre-exposure prophylaxis for high-risk groups, later expanding to include broader demographics as domestic cases rose. By April 2024, a total of 6,863 individuals had received their first vaccine dose, with 3,875 completing the second dose of third-generation vaccines. Strategies to improve future responses include addressing stigma, securing nationally representative safety data, and conducting vaccine cost-benefit analyses. These measures will help ensure a robust and effective response to future outbreaks.</p>\",\"PeriodicalId\":16249,\"journal\":{\"name\":\"Journal of Korean Medical Science\",\"volume\":\"39 32\",\"pages\":\"e235\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333806/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Korean Medical Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3346/jkms.2024.39.e235\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e235","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

2024 年 5 月 1 日,大韩民国在报告首例麻风腮病例近两年后解除了传染病危机警报。韩国疾病预防控制机构(KDCA)领导了包括诊断、流行病学调查、治疗和疫苗接种在内的应对工作。本文特别回顾了所实施的疫苗接种策略,并提出了加强未来应对工作的建议。起初,韩国疾控中心建议对高危人群进行接触前预防,后来随着国内病例的增加而扩大到更广泛的人群。截至 2024 年 4 月,共有 6863 人接种了第一剂疫苗,其中 3875 人接种了第二剂第三代疫苗。改善未来应对措施的战略包括解决污名化问题、确保具有全国代表性的安全数据以及进行疫苗成本效益分析。这些措施将有助于确保对未来的疫情爆发做出有力而有效的反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response.

On May 1, 2024, the Republic of Korea lifted the infectious disease crisis alert for mpox, almost two years after the first case was reported. The Korea Disease Control and Prevention Agency (KDCA) has led the response, which included diagnosis, epidemiological investigations, treatment, and vaccination. This article particularly reviews the vaccination strategy implemented and proposes suggestions for enhancing future response efforts. Initially, the KDCA recommended pre-exposure prophylaxis for high-risk groups, later expanding to include broader demographics as domestic cases rose. By April 2024, a total of 6,863 individuals had received their first vaccine dose, with 3,875 completing the second dose of third-generation vaccines. Strategies to improve future responses include addressing stigma, securing nationally representative safety data, and conducting vaccine cost-benefit analyses. These measures will help ensure a robust and effective response to future outbreaks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Korean Medical Science
Journal of Korean Medical Science 医学-医学:内科
CiteScore
7.80
自引率
8.90%
发文量
320
审稿时长
3-6 weeks
期刊介绍: The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信